Advertisement
Singapore markets closed
  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     
  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • FTSE 100

    8,123.13
    +44.27 (+0.55%)
     
  • Bitcoin USD

    63,929.76
    +719.34 (+1.14%)
     
  • CMC Crypto 200

    1,378.39
    -18.15 (-1.30%)
     
  • S&P 500

    5,082.27
    +33.85 (+0.67%)
     
  • Dow

    38,120.48
    +34.68 (+0.09%)
     
  • Nasdaq

    15,822.08
    +210.32 (+1.35%)
     
  • Gold

    2,356.90
    +14.40 (+0.61%)
     
  • Crude Oil

    84.38
    +0.81 (+0.97%)
     
  • 10-Yr Bond

    4.6750
    -0.0310 (-0.66%)
     
  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     
  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     
  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Exploring Voyager Therapeutics’ Cash Flows and Valuation Metrics

Exploring Voyager Therapeutics’ Cash Flows and Valuation Metrics

Voyager Therapeutics (VYGR) spent $61.3 million on operating activities in 2017 compared to $42.4 million in 2016. In comparison, it generated $47.3 million from investing activities in 2016. The company’s positive investing cash flow in 2016 was attributable to proceeds from the maturities of marketable securities of $165.1 million, and it was partially offset by securities purchases of $112.4 million.